Research programme: anti-infectives - Zymenex/Genmab

Drug Profile

Research programme: anti-infectives - Zymenex/Genmab

Alternative Names: ACE-5001; ACE-5003; ACE-5033

Latest Information Update: 11 Nov 2009

Price : $50

At a glance

  • Originator ACE BioSciences
  • Developer Zymenex A/S
  • Class Antibodies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Aspergillosis; Mycoses

Most Recent Events

  • 09 Nov 2009 ACE BioSciences has been acquired by Zymenex A/S
  • 06 Mar 2008 Preclinical development is ongoing
  • 20 Nov 2003 Preclinical trials in Aspergillosis in Denmark (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top